Clinical Trial Detail

NCT ID NCT03626545
Title Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Canakinumab + Docetaxel

Docetaxel

Age Groups: adult senior

Additional content available in CKB BOOST